Document Type : Research Article
Background: As the pandemic of Coronavirus disease (COVID-19) progresses, health care remains a new challenge. The recent rise in second wave possess a different challenge of opportunistic infections especially Mucormycosis in COVID-19 recovered patients. It is complicating their future outcomes and making quality of life more Morbid. Mucormycosis was well known to infect patients with immunocompromised conditions, as the treatment of COVID-19 largely rests on systemic steroids and other immunosuppressant’s the risk of invasive fungal infection has increased.
Methodology: Here, we present a case series of 07 patients with individual clinical characteristics along with the demography and treatment details studied during 3 months June 2021 to August 2021. The data was collected in a single center that caters to a large population of COVID-19 patients with varying severity in taluka places of Maharashtra.
Results: seven patients were presented with COVID-19 associated Rhino-orbito-cerebral Mucormycosis. The median age was higher in non-survivors (59.5 years), with a higher odds ratio of death (23.8) in those with severe COVID, having overall mortality of 57 %. Moreover, diabetes mellitus was present in 70% of patients with a mortality of 57%. All patients had received prior steroids for COVID-19 management. The incidence of hyperglycemia at admission was equal among both survivors and non-survivors.
Conclusion: The prevalence of Mucormycosis seems to be more among COVID-19 patients which may be due to with increased use of systemic steroids, and immunocompromised state because by SARS-CoV-2, or conditions such as diabetes mellitus. As the mortality of Mucormycosis is remarkably high and apart from preventive practices and rational use of immunomodulators, a high index of suspicion with early diagnosis is needed.